Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H21N5O3 |
| Molecular Weight | 367.4017 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(NC3=C4C(=CC=C3[N+]([O-])=O)N(CCCN(C)C)N=C24)C=C1
InChI
InChIKey=HZCWPKGYTCJSEB-UHFFFAOYSA-N
InChI=1S/C19H21N5O3/c1-22(2)9-4-10-23-15-7-8-16(24(25)26)19-17(15)18(21-23)13-11-12(27-3)5-6-14(13)20-19/h5-8,11,20H,4,9-10H2,1-3H3
| Molecular Formula | C19H21N5O3 |
| Molecular Weight | 367.4017 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pyrazoloacridine is a pyrazolo[3,4,5-kl]acridine derivative patented by Warner-Lambert Co. as an anticancer agent. Pyrazoloacridine acts as topoisomerase I and II inhibitor that decrease the formation of topoisomerase-DNA adducts. In vitro experiments, Pyrazoloacridine shows efficacy against multidrug-resistant neuroblastoma doxorubicin-resistant human colon carcinoma and breast cancer cell lines. In clinical trials, Pyrazoloacridine demonstrates moderate efficacy in metastatic breast cancer and a high level of adverse events. The dose-limiting toxicity was grade 4 neutropenia. Other grade 3 and 4 toxicities include vomiting, nausea, neurotoxicity, fatigue, and anemia.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study. | 2002-08 |
|
| Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. | 2000-05 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:05:09 GMT 2025
by
admin
on
Mon Mar 31 20:05:09 GMT 2025
|
| Record UNII |
L24XJN68OW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2161
Created by
admin on Mon Mar 31 20:05:09 GMT 2025 , Edited by admin on Mon Mar 31 20:05:09 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
99009-20-8
Created by
admin on Mon Mar 31 20:05:09 GMT 2025 , Edited by admin on Mon Mar 31 20:05:09 GMT 2025
|
PRIMARY | |||
|
L24XJN68OW
Created by
admin on Mon Mar 31 20:05:09 GMT 2025 , Edited by admin on Mon Mar 31 20:05:09 GMT 2025
|
PRIMARY | |||
|
DB12549
Created by
admin on Mon Mar 31 20:05:09 GMT 2025 , Edited by admin on Mon Mar 31 20:05:09 GMT 2025
|
PRIMARY | |||
|
339455
Created by
admin on Mon Mar 31 20:05:09 GMT 2025 , Edited by admin on Mon Mar 31 20:05:09 GMT 2025
|
PRIMARY | |||
|
627168
Created by
admin on Mon Mar 31 20:05:09 GMT 2025 , Edited by admin on Mon Mar 31 20:05:09 GMT 2025
|
PRIMARY | |||
|
DTXSID301316714
Created by
admin on Mon Mar 31 20:05:09 GMT 2025 , Edited by admin on Mon Mar 31 20:05:09 GMT 2025
|
PRIMARY | |||
|
C1564
Created by
admin on Mon Mar 31 20:05:09 GMT 2025 , Edited by admin on Mon Mar 31 20:05:09 GMT 2025
|
PRIMARY | NCIT | ||
|
366140
Created by
admin on Mon Mar 31 20:05:09 GMT 2025 , Edited by admin on Mon Mar 31 20:05:09 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
